← Back to Search

Central Nervous System Stimulant

Stimulant Medication for ADHD

Phase 2
Recruiting
Led By Cynthia M Hartung, Ph.D.
Research Sponsored by University of Wyoming
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up completed the day after each experimental appointment over a period of two weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trialwill examine if stimulants improve executive functioning in college students with ADHD but not those without, to better understand efficacy and prevent misuse.

Who is the study for?
This trial is for college students aged 18-29 with ADHD who have been previously diagnosed and report significant inattention symptoms. They must be native English speakers, not pregnant, non-smokers, and not using conflicting medications or substances. Healthy peers without ADHD are also included as controls if they match an ADHD participant's age and sex.
What is being tested?
The study tests the immediate effects of Adderall IR (a stimulant medication) on executive functioning in college students with ADHD compared to a placebo. The goal is to see if Adderall improves attention and working memory better than no treatment at all.
What are the potential side effects?
Potential side effects of Adderall may include nervousness, restlessness, difficulty sleeping, dry mouth, headache, changes in sex drive or ability; gastrointestinal issues like diarrhea or constipation; and potentially more serious heart-related issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~completed the day after each experimental appointment over a period of two weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and completed the day after each experimental appointment over a period of two weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Addiction Research Center Inventory (ARCI) for Adderall vs. Placebo
Change in Continuous Performance Test - Identical Pairs (CPT-IP) for Adderall vs. Placebo
Change in Digit Span for Adderall vs. Placebo
+4 more
Secondary study objectives
DSM-5 ADHD Symptoms Checklist - Modified (DSM 5-M)
Depression, Anxiety, and Stress Scale-Modified (DASS-M)
Pittsburgh Sleep Quality Index-Modified (PSQI-M)
+2 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stimulant MedicationExperimental Treatment2 Interventions
Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

University of WyomingLead Sponsor
18 Previous Clinical Trials
1,496 Total Patients Enrolled
1 Trials studying Working Memory
48 Patients Enrolled for Working Memory
Cynthia M Hartung, Ph.D.Principal Investigator - University of Wyoming
University of Wyoming
1 Previous Clinical Trials
48 Total Patients Enrolled
1 Trials studying Working Memory
48 Patients Enrolled for Working Memory

Media Library

Adderall IR 10mg (Central Nervous System Stimulant) Clinical Trial Eligibility Overview. Trial Name: NCT03935646 — Phase 2
Working Memory Research Study Groups: Stimulant Medication
Working Memory Clinical Trial 2023: Adderall IR 10mg Highlights & Side Effects. Trial Name: NCT03935646 — Phase 2
Adderall IR 10mg (Central Nervous System Stimulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03935646 — Phase 2
~4 spots leftby Jun 2025